Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis

View source ↗

GPR109A expressed in immune cells as well as in colonic tissue is necessary for protection against colitis and colon carcinogenesis. Niacin suppresses colitis and colon cancer in a GPR109A-dependent manner. GPR109A is key in mediating the beneficial effects of gut microbiota and dietary fiber in colon. Niacin suppresses atherosclerosis by activating GPR109A in immune cells. GPR109A mediates butyrate effects in colon and is a critical molecular link between colonic bacteria and dietary fiber and the host.

Overview

This 2014 Cell Immunity paper (Thangaraju et al.) is one of the most cited in the GPR109A literature. It demonstrates that GPR109A — the receptor activated by both niacin and the gut metabolite butyrate — plays a protective role against colonic inflammation and colon cancer. The study establishes GPR109A as a critical molecular link between the gut microbiome, dietary fiber, and host immune defense.

Key Findings

GPR109A is required for colonic immune protection. Mice lacking GPR109A showed increased susceptibility to colitis and colon carcinogenesis when challenged with inflammation-inducing agents. This indicates GPR109A's function is not redundant — it is necessary, not just helpful.

Niacin suppresses colitis and colon cancer via GPR109A. When GPR109A was activated by niacin in wild-type mice, colitis was suppressed. In GPR109A-knockout mice, niacin had no protective effect — confirming the mechanism is GPR109A-dependent, not a general effect of niacin on inflammation.

Butyrate activates GPR109A in the colon. The short-chain fatty acid butyrate — produced by gut bacteria fermenting dietary fiber — also activates GPR109A. This discovery positioned GPR109A as the receptor mediating the well-known anti-inflammatory and anti-cancer effects of dietary fiber and a healthy gut microbiome.

GPR109A induces IL-18 in colonocytes and Treg differentiation. The mechanism involves GPR109A activation inducing production of interleukin-18 (IL-18) in colon epithelial cells, which then promotes regulatory T cell (Treg) differentiation — suppressing excessive immune response while maintaining tolerance.

The Broader Picture

This paper describes a coherent circuit:

  1. Dietary fiber → gut bacteria ferment it → butyrate produced
  2. Butyrate activates GPR109A on colonic epithelial cells and immune cells
  3. GPR109A activation → IL-18 secretion from colonocytes
  4. IL-18 → Treg differentiation → suppression of colonic inflammation
  5. Disruption of this circuit (dysbiosis, low fiber, GPR109A loss) → colitis, increased cancer risk

Niacin, as a pharmacological agonist of GPR109A, can activate this circuit even when dietary butyrate is insufficient — for example, in patients with dysbiosis or low-fiber diets.

Niacin and Atherosclerosis: Same Receptor

The paper also notes that GPR109A activation by niacin suppresses atherosclerosis via immune cells, specifically by reducing macrophage activation. This connects niacin's lipid-modifying effects and its anti-inflammatory effects through the same receptor.

Why This Matters

This study explains why:

  • Niacin (nicotinic acid) has anti-inflammatory effects in the colon at therapeutic doses
  • The gut microbiome matters for colon cancer prevention
  • Dietary fiber has protective effects that are mechanistically explainable
  • Niacinamide would not produce these same GPR109A-mediated effects in the colon

For researchers and clinicians investigating niacin in inflammatory bowel disease, colon cancer prevention, or the gut-immune axis, this Cell Immunity paper is the foundational reference for GPR109A's role in colonic biology.